Scientific Research Test

Project name

NMDAR (N-methyl-D-aspartate receptor)

AMPA1 (GluA1, glutamate receptor A1)

AMPA2 (GluA2, glutamate receptor A2)

LGI1 (Leucine-rich glioma-inactivated protein 1)

CASPR2 (Contactin-associated protein-like 2)

GABA (γ-Aminobutyric acid receptor)

Detection method

Cell-based assay (CBA)

Project name

Jo-1、 PL-7、PL-12、 EJ、 SRP、 Mi-2、 MDA-5、 TIF1-γ、 HMGCR、 SSA/Ro52kD SAE-1/2、 NXP-2

Detection method

Western blot

Project name

Hu, Yo, Ri,

CV2(CRMP5) (collapsin response mediator protein 5) collapsin, Ma1(PNMA1) (Paraneoplastic antigen Ma1), Ma2(PNMA2) (Paraneoplastic antigen Ma2), Tr, SOX1, Zic4, GAD65(glutamic acid decarboxylase)

Amphiphysin

Detection method

Western blot

Project name

GM1、GM2、GM3、GM4、GD1a、GD1b、GD2、GD3

GT1a、GT1b、GQ1b、sulfatides (IgG+IgM)

Detection method

Western blot

Project name

AchR（Acetylcholine receptor）

Musk（muscle-specific tyrosine kinase）

Detection method

TSA-CBA

Project name

S100β

Detection method

Immunochromatography of gold magnetic particles

Project name

B-cell assay

Detection method

Flow cytometry: Peripheral blood CD19+%, CD5+CD19+/CD19+, and CD20+% were determined by flow cytometry in rituximab patients.

Project name

Type of immune cells (lymphocytes, myeloid cells)

Detection method

The proportion of immune cells in peripheral blood was monitored after immunotherapy

Single-molecule array (Simoa) technology enables ultrasensitive protein detection that is suited to the development of peripheral blood-based assays for assessing neurological disorders. Simoa technology is based on the Quanterix Simoa HD-1 digital single molecular array analyzer, which can directly perform ultra-high sensitivity detection of biomarkers such as proteins and nucleic acids in serum and plasma. The advent of Simoa technology has changed the situation where neural markers could only be detected in cerebrospinal fluid in the past. At present, neurological biomarkers can be detected in peripheral blood using Simoa technology, thus changing the way of diagnosis of brain injury and neurodegenerative diseases. Simoa enables accurate quantitation of soluble immune signaling molecules in an unprecedented femtomolar range. In addition, Simoa technology has also greatly promoted the early detection of cancer, postoperative monitoring and precision medicine. Its main application areas include nerves, tumors, infectious diseases and immune inflammation. At present, there are hundreds of publications citing this technology in the world, including Nature, Science, Cell, Lancet, Nature Biotechnology, The Lancet Neurology, JAMA Neurology, etc.

技术原理

A high-level look at a Simoa Bead-based assay, from development to data analysis: (1) Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample. (2) Detection antibodies – capable of generating fluorescent product – are added. (3) The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody. (4) At low concentrations, each bead will contain one bound protein, or none. (5) The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead. (6) Enzymatic signal amplification with fluorescent substrate, fluorescence imaging and data reduction. (7) Data analysis – results can be viewed and analyzed on the board or exported to commonly used software packages or LIMS systems.

技术优势

High sensitivity: More than 1000 times more sensitive than ELISA

Full-automation: Ensure repeatability and accuracy of results

Multiplex detection: Detect multiple target molecules each time

Wide linear range: Detection dynamic range more than 4 orders of magnitude

High precision: Experimental results of batch-to-batch variation coefficient (CVs) below 10%

Self-development: Suitable for scientific innovation